Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.4735 | 0.4865 | 0.0140 | 0.0000 | Inf | 0.060078 |
| HCC70 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.9348 | -0.0227 | 0.0035 | 0.0000 | Inf | 0.040075 |
| HCC1806 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 1.0500 | -0.0207 | -0.0033 | 0.0000 | Inf | -0.67606 |
| MDA-MB-134-VI | A-1210477 | Mcl-1 | Misc | Inf | 1.0500 | -0.0366 | -0.0033 | 0.0000 | Inf | -3.0589 |
| CAL-120 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 1.0198 | -0.0168 | -0.0059 | 0.0000 | Inf | -0.45144 |
| BT-20 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 1.0152 | -0.0415 | -0.0034 | 0.0000 | Inf | -7.4504 |
| HCC70 | A-1210477 | Mcl-1 | Misc | Inf | 0.9380 | 0.0054 | 0.0123 | 0.0000 | Inf | 0.17964 |
| MDA-MB-134-VI | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.8589 | -0.0381 | -0.0029 | 0.0000 | Inf | 0.38211 |
| HCC1937 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0500 | -0.0406 | -0.0017 | 0.0000 | Inf | -4.6521 |
| CAL-51 | A-1210477 | Mcl-1 | Misc | Inf | 0.9919 | 0.0073 | 0.0004 | 0.0000 | Inf | 0.00046652 |
| MDA-MB-436 | A-1210477 | Mcl-1 | Misc | Inf | 0.8728 | 0.0140 | 0.0010 | 0.0000 | Inf | 0.42977 |
| MDA-MB-468 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0457 | -0.0214 | 0.0005 | 0.0000 | Inf | -0.58792 |
| PDXHCI002 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.8732 | -0.0268 | -0.0011 | 0.0000 | Inf | 0.45924 |
| SK-BR-3 | ABT-737 | Bcl2/XL | Misc | Inf | 0.9470 | -0.0148 | 0.0045 | 0.0000 | Inf | 0.12804 |
| BT-549 | ABT-737 | Bcl2/XL | Misc | Inf | 0.9359 | -0.0225 | 0.0062 | 0.0000 | Inf | 0.067883 |
| HCC1500 | Everolimus | mTOR1 | PI3K/mTOR | Inf | -0.3096 | 1.2601 | 0.2328 | 0.0000 | Inf | 0.51907 |
| MDA-MB-134-VI | Dasatinib | BCR/ABL | MAPK/nRTK | Inf | 0.8878 | -0.0289 | 0.0187 | 0.0000 | Inf | 0.37857 |
| MDA-MB-134-VI | Saracatinib | SRC | MAPK/nRTK | Inf | 1.0500 | -0.0500 | 0.0181 | 0.0000 | Inf | -Inf |
| MDA-MB-436 | Dasatinib | BCR/ABL | MAPK/nRTK | Inf | 0.6528 | 0.1022 | 0.0098 | 0.0000 | Inf | 0.40773 |
| SK-BR-3 | Everolimus | mTOR1 | PI3K/mTOR | -Inf | 0.1182 | 0.7944 | 0.1209 | 0.1000 | 6.3064e-07 | 0.84606 |
| HCC1428 | Everolimus | mTOR1 | PI3K/mTOR | 0.031039 | 0.3462 | 0.5186 | 0.0192 | 0.1000 | 0.0006981 | 0.70927 |
| CAMA-1 | Everolimus | mTOR1 | PI3K/mTOR | -Inf | 0.1642 | 0.7666 | 0.0258 | 0.1000 | 1.9385e-07 | 0.61758 |
| T47D | Everolimus | mTOR1 | PI3K/mTOR | -Inf | 0.2975 | 0.6157 | 0.0150 | 0.1000 | 5.9599e-07 | 0.77906 |
| HCC1143 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.5574 | 0.3426 | 0.0295 | 0.1006 | 0.071342 | 0.79962 |
| HCC70 | Everolimus | mTOR1 | PI3K/mTOR | 0.24351 | 0.3727 | 0.4764 | 0.0448 | 0.1135 | 51.0339 | 0.79604 |